Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
Ultrasound Med Biol. 2012 Feb;38(2):335-45. doi: 10.1016/j.ultrasmedbio.2011.11.009.
Left ventricular assist devices (LVAD) are being deployed increasingly in patients with severe left ventricular dysfunction and medically refractory congestive heart failure of any etiology. The United States Food and Drug Administration (FDA) recently approved the use of the Thoratec Heartmate II (Thoratec Corporation, Pleasanton, CA, USA) for outpatient use. Echocardiography is fundamental during each stage of patient management, pre-LVAD placement, during LVAD placement, for postoperative LVAD optimization and long-term follow-up. We present a pragmatic and systematic echocardiographic approach that serves as a guide for the management of left ventricular assist devices.
左心室辅助装置（LVAD）在患有严重左心室功能障碍和任何病因导致的药物难治性充血性心力衰竭的患者中越来越多地得到应用。美国食品和药物管理局（FDA）最近批准了 Thoratec Heartmate II（Thoratec 公司，美国加利福尼亚州普莱森顿）用于门诊使用。在患者管理的每个阶段，包括 LVAD 植入前、LVAD 植入期间、术后 LVAD 优化和长期随访期间，超声心动图都是至关重要的。我们提出了一种实用且系统的超声心动图方法，作为左心室辅助装置管理的指南。
